000			01752cam a2200181 4500500
005			20251012013307.0
041			_afre
042			_adc
100	1	0	_aFonteneau, Jean-François _eauthor
700	1	0	_a Boisgerault, Nicolas _eauthor
700	1	0	_a Tangy, Frédéric _eauthor
245	0	0	_aAntitumor immuno-virotherapy with attenuated strains of measles virus
260			_c2025.
500			_a5
520			_aAntitumor immuno-virotherapy involves the use of replicating oncolytic viruses capable of selectively infecting and killing tumor cells, with the aim of stimulating an antitumor immune response. Attenuated strains of measles virus (MeV) used as measles vaccines are good candidates. Attenuated MeVs use the CD46 molecule as a tumor cell entry receptor, but also CD150/SLAM and Nectin-4. The CD46 molecule blocks complement-mediated lysis and is frequently overexpressed by many cancer cell types, enabling the attenuated MeV to infect these cells. In addition, MeVs take advantage of defects in the antiviral type I interferon (IFN I) response in tumor cells to replicate, while this antiviral response blocks its replication in healthy cells. Attenuated MeVs display oncolytic properties against numerous cancers in vitro and in mouse models. They induce immunogenic cell death with infiltration of tumors by immune cells, notably T lymphocytes, thus activating the anti-tumor immune response. Several phase I and II clinical trials using different MeVs have been carried out, with encouraging results. Here, we provide an update on this therapeutic approach.
786	0		_nVirologie | 29 | 4 | 2025-09-03 | p. 271-291 | 1267-8694
856	4	1	_uhttps://shs.cairn.info/journal-virologie-2025-4-page-271?lang=en&redirect-ssocas=7080
999			_c1529045 _d1529045